Literature DB >> 10752984

Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis.

C Vener1, A Guffanti, M Pomati, M Colombi, A Alietti, M L La Targia, F Bamonti-Catena, L Baldini.   

Abstract

The serum levels of some cytokines seem to correlate with outcome in Hodgkin's disease (HD) and may be helpful in formulating new and better prognostic systems. The aim of this study was to analyse the correlations between the serum levels of different cytokines and the clinico-hematological features suggestive of a worse prognosis. The study involved 31 pts with a "de novo" diagnosis of HD (median age: 30 yrs; M/F: 13/18; stage I/II vs III/IV: 19/12; B symptoms: 12; bulky disease and extranodal disease: 9). The serum levels of sCD30, TNFalpha, TNF receptor I and II, IL6, IL6 receptor, IL10, sICAM-1 were evaluated at diagnosis, and correlated with gender, age (< or =/> 30), stage (I-II vs III-IV), systemic symptoms, bulky disease, ESR (</> or = 40), serum copper (< or =/> 170 microg/dL), WBC counts (< or =/> 15x10(9)/L), prognostic scores (PS) according to Hasenclever (</> or = 2), and the presence of extranodal disease. Stages III/IV were associated with significantly higher levels of sCD30 and TNF-RI (p=0.03), systemic symptoms with significantly higher levels of sCD30, TNFalpha, IL6, TNF-RI (p=0.027, 0.03, 0.0005, 0.002), bulky disease with TNF-RI (p=0.03), high ESR with IL6 and TNF-RI (p=0.0011, 0.0001), high WBC counts with sCD30, IL6, TNF-RI (p=0.03, 0.002, 0.01), high serum copper with sCD30 and IL6 (p=0.05, 0.0004), higher PS with sCD30, IL6, TNF-RI (p=0.002, 0.0003, 0.005), extranodal disease with TNFalpha and IL6 (p=0.05, 0.01). It was possible to define cut-off levels for some cytokines (sCD30 > 33.15 U/mL, TNFalpha > 29.71 pg/mL, IL6 > 12.43 pg/mL, TNF-RI > 3.23 ng/mL, IL6-R > 57 ng/mL) that significantly correlate with systemic symptoms, higher disease stages, ESR, serum copper, WBC counts and PS. Our study shows that high sCD30, TNFalpha, IL6 and TNF-RI levels are associated with advanced disease or a worse prognostic score. In the context of multiparametric HD staging, cytokine evaluation may be useful for identifying candidates for more intensive therapies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10752984     DOI: 10.3109/10428190009089433

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma.

Authors:  Maria Kowalska; Joanna Tajer; Magdalena Chechlinska; Malgorzata Fuksiewicz; Beata Kotowicz; Małgorzata Syczewska; Jan Walewski; Janina Kaminska
Journal:  Tumour Biol       Date:  2012-06-08

2.  Dietary pattern and risk of hodgkin lymphoma in a population-based case-control study.

Authors:  Mara M Epstein; Ellen T Chang; Yawei Zhang; Teresa T Fung; Julie L Batista; Richard F Ambinder; Tongzhang Zheng; Nancy E Mueller; Brenda M Birmann
Journal:  Am J Epidemiol       Date:  2015-07-15       Impact factor: 4.897

3.  Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma.

Authors:  Maria Kowalska; Joanna Tajer; Magdalena Chechlinska; Malgorzata Fuksiewicz; Beata Kotowicz; Janina Kaminska; Jan Walewski
Journal:  Med Oncol       Date:  2011-06-30       Impact factor: 3.064

4.  The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker.

Authors:  Rosaria Cammarota; Valentina Bertolini; Giuseppina Pennesi; Eraldo O Bucci; Ornella Gottardi; Cecilia Garlanda; Luigi Laghi; Massimo C Barberis; Fausto Sessa; Douglas M Noonan; Adriana Albini
Journal:  J Transl Med       Date:  2010-11-08       Impact factor: 5.531

5.  Common genetic variants in candidate genes and risk of familial lymphoid malignancies.

Authors:  Xueying Sharon Liang; Neil Caporaso; Mary Lou McMaster; David Ng; Ola Landgren; Meredith Yeager; Stephen Chanock; Lynn R Goldin
Journal:  Br J Haematol       Date:  2009-07-01       Impact factor: 6.998

6.  Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma.

Authors:  Preethi Reddy Marri; Lucy S Hodge; Matthew J Maurer; Steven C Ziesmer; Susan L Slager; Thomas M Habermann; Brian K Link; James R Cerhan; Anne J Novak; Stephen M Ansell
Journal:  Clin Cancer Res       Date:  2013-10-18       Impact factor: 12.531

7.  Development of a rapid streptavidin capture-based assay for the tyrosine phosphorylated CSF-1R in peripheral blood mononuclear cells.

Authors:  Shalini Chaturvedi; Elayne Dell; Derick Siegel; Gregory Brittingham; Shobha Seetharam
Journal:  Int J Biol Sci       Date:  2013-11-22       Impact factor: 6.580

8.  The reciprocal interplay between TNFα and the circadian clock impacts on cell proliferation and migration in Hodgkin lymphoma cells.

Authors:  Mónica Abreu; Alireza Basti; Nikolai Genov; Gianluigi Mazzoccoli; Angela Relógio
Journal:  Sci Rep       Date:  2018-07-31       Impact factor: 4.379

9.  Interim interleukin 6 levels correlate with progression-free survival in patients with classic Hodgkin's disease: a pilot study.

Authors:  Pamela Villanova; Vitor Augusto Queiroz Mauad; Davimar Miranda Maciel Borducchi; Auro Del Giglio
Journal:  Hematol Transfus Cell Ther       Date:  2019-03-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.